

---

## Press Release

---

April 27, 2026

Sumitomo Pharma Co., Ltd.

### **Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE; the “Company”) announced today that it has withdrawn the shelf registration statement for issuance of new shares (the “Shelf Registration Statement”) announced in the notice “Announcement of Filing of Shelf Registration Statement for Issuance of New Shares” dated March 2, 2026.

#### 1. Summary of the Withdrawn Shelf Registration Statement

- |  |  |
|--|--|
| 1. Submission Date of the Shelf Registration Statement | March 2, 2026  |
| 2. Class of Securities to be Offered                   | Common stock of the Company  |
| 3. Scheduled Period of Issuance                        | From the effective date of the shelf registration to the date that is one year from the effective date (from March 10, 2026 through March 9, 2027)         |
| 4. Scheduled Amount of Issuance                        | A maximum amount of 140 billion yen.<br>(Note) As described in 2. below, 41,582,735,152 yen (total amount of issue price) of new shares have been offered. |

#### 2. Issuance Results under the Shelf Registration Statement

Total Amount of Issue Price: 41,582,735,152 yen

(Note) The Company has sold shares of its common stock (total amount of issue price: 56,258,860,000 yen) in overseas markets (in the United States, restricted to sales to Qualified Institutional Buyers under Rule 144A of the U.S. Securities Act of 1933), concurrently with the offering conducted through the shelf registration described above.

#### 3. Reason for Withdrawal of the Shelf Registration Statement

Note:	This press release is a general release regarding the withdrawal of a shelf registration statement in Japan for the issuance of new shares of common stock of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.
-------	---

The Shelf Registration Statement has been withdrawn because the offering of shares scheduled to be conducted through the shelf registration has been completed.

Other than the above, a maximum of 7,695,600 shares of the common stock of the Company may be issued on May 26, 2026 upon the third-party allotment with the designated Japanese underwriter in relation to the secondary offering by way of over-allotment. For details thereof, please see the notice "Notice Regarding Issuance of New Shares and Secondary Offering of Shares" dated April 8, 2026 and "Notice Regarding Determination of Issue Price, Selling Price and Other Matters" dated April 20, 2026.

End.

Contact:

Corporate Communications,

Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)

<p>Note: This press release is a general release regarding the withdrawal of a shelf registration statement in Japan for the issuance of new shares of common stock of the Company, and is not prepared for the purpose of investment solicitation or the like in Japan or elsewhere. This press release does not constitute an offer to sell or solicitation of any offer to buy securities in the United States. The shares of common stock of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The shares of common stock of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. No public offering of the shares of common stock of the Company will take place in the United States.</p>
--